| Literature DB >> 35729670 |
Xue Tian1,2, Yingting Zuo1,2, Shuohua Chen3, Shouling Wu4, Anxin Wang5,6, Yanxia Luo7,8.
Abstract
BACKGROUND: Long-term patterns of serum uric acid (SUA) and their association with the risk of myocardial infarction (MI) and mortality are poorly characterized as prior studies measured SUA at a single time point. This study aimed to identify SUA trajectories and determine their associations with incident MI and all-cause mortality.Entities:
Keywords: All-cause mortality; Myocardial infarction; Serum uric acid; Trajectories
Mesh:
Substances:
Year: 2022 PMID: 35729670 PMCID: PMC9210742 DOI: 10.1186/s13075-022-02812-y
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.606
Fig. 1The time line and flowchart of the study. Abbreviations: MI, myocardial infarction; SUA, serum uric acid
Fig. 2The trajectories of serum uric acid over 6 years
Baseline characteristics of participants per trajectory of SUA
| SUA trajectory group | |||||
|---|---|---|---|---|---|
| Characteristics | Overall | Low-stable | Moderate-stable | High-stable | |
| Subjects, | 85,503 | 44,124 | 34,431 | 6948 | |
| Age, years | 50±12 | 50±11 | 50±13 | 51±12 | <0.0001 |
| Men, | 66,808 (78.1) | 29,615 (67.1) | 30,523 (88.6) | 6670 (96.0) | <0.0001 |
| High school or above, | 6074 (7.3) | 2457 (5.7) | 2785 (8.3) | 832 (12.2) | <0.0001 |
| Income≥800RMB, | 12,172 (14.6) | 5090 (11.8) | 5642 (16.8) | 1440 (21.2) | <0.0001 |
| Current smoker, | 29,102 (34.8) | 11,301 (26.2) | 14,416 (42.8) | 3385 (49.7) | <0.0001 |
| Alcohol use, | |||||
| Never or past | 43,744 (66.3) | 25,787 (75.1) | 15,377 (58.7) | 2580 (47.2) | <0.0001 |
| Light | 18,271 (27.7) | 6866 (20.0) | 9065 (34.6) | 2340 (42.8) | |
| Moderate | 3428 (5.2) | 1513 (4.4) | 1485 (5.7) | 4300 (7.9) | |
| Heavy | 370 (0.6) | 117 (0.3) | 168 (0.6) | 85 (1.6) | |
| Active physical activity, | 75,978 (91.02) | 39,484 (91.6) | 30,340 (90.3) | 6154 (90.8) | <0.0001 |
| Hypertension, | 36,250 (42.4) | 17,421 (39.5) | 15,308 (44.5) | 3521 (50.7) | <0.0001 |
| Diabetes mellitus, | 7411 (8.7) | 4420 (10.0) | 2552 (7.4) | 439 (6.3) | <0.0001 |
| Dyslipidemia, | 29,952 (35.0) | 13,180 (29.9) | 13,223 (38.4) | 3549 (51.1) | <0.0001 |
| Metabolic syndrome, | 14,717 (17.2) | 6006 (13.6) | 6857 (19.9) | 1854 (26.7) | <0.0001 |
| Antihypertensive agents, | 8982 (10.5) | 3039 (6.9) | 4516 (13.1) | 1427 (20.5) | <0.0001 |
| Hypoglycemic agents, | 1898 (2.2) | 1047 (2.4) | 709 (2.1) | 142 (2.0) | 0.0073 |
| Lipid-lowering agents, | 777 (0.9) | 269 (0.6) | 395 (1.2) | 113 (1.6) | <0.0001 |
| Body mass index, kg/m2 | 25±3 | 24±3 | 25±3 | 26±3 | <0.0001 |
| Systolic blood pressure, mmHg | 130±20 | 128±20 | 131±20 | 134±21 | <0.0001 |
| Diastolic blood pressure, mmHg | 83±11 | 82±11 | 84±11.82 | 86±12 | <0.0001 |
| Fasting blood glucose, mmol/L | 5.4±1.6 | 5.5±1.7 | 5.3±1.3 | 5.4±1.5 | <0.0001 |
| Total cholesterol, mmol/L | 4.9±1.1 | 4.8±1.2 | 5.1±1.0 | 5.2±1.1 | <0.0001 |
| eGFR, mL/min/1.73m2 | 82±25 | 83±23 | 83±27 | 80±25 | <0.0001 |
| hs-CRP, mg/L | 2.3±6.2 | 2.0±5.7 | 2.9±6.4 | 3.0±7.2 | <0.0001 |
| SUA | 287±82 | 236±53 | 324±58 | 425±74 | <0.0001 |
Continuous variables were expressed as mean ± standard deviation and were compared with ANOVA, and categorical variables were expressed as frequency with proportion and were compared with chi-square test
Abbreviations: eGFR estimated glomerular filtration rate, hs-CRP high-sensitivity C-reactive protein; SUA, serum uric acid
HRs (95% CIs) for incident myocardial infarction and all-cause mortality per trajectory of SUA trajectories
| SUA trajectory group | ||||
|---|---|---|---|---|
| Low-stable | Moderate-stable | High-stable | ||
| Myocardial infarction | ||||
| Cases, n (%) | 342 (0.78) | 372 (1.08) | 103 (1.48) | <0.0001 |
| Incidence ratea | 1.18 (1.07–1.32) | 1.66 (1.50–1.84) | 2.29 (1.89–2.77) | |
| Model 1 | Reference | 1.41 (1.21–1.63) | 1.94 (1.56–2.42) | <0.0001 |
| Model 2 | Reference | 1.14 (0.98–1.32) | 1.53 (1.22–1.91) | <0.0001 |
| Model 3 | Reference | 1.10 (0.95–1.28) | 1.35 (1.07–1.71) | 0.0146 |
| Sensitivity analysisb | Reference | 1.09 (0.93–1.27) | 1.33 (1.05–1.67) | 0.0264 |
| Sensitivity analysisc | Reference | 1.06 (0.88–1.28) | 1.50 (1.14–1.97) | 0.0158 |
| Sensitivity analysisd | Reference | 1.06 (0.91–1.23) | 1.33 (1.06–1.66) | 0.0317 |
| Sensitivity analysise | Reference | 1.10 (0.94–1.28) | 1.33 (1.05–1.68) | 0.0246 |
| All-cause mortality | ||||
| Cases, | 2886 (6.54) | 2884 (8.38) | 728 (10.48) | <0.0001 |
| Incidence rate | 9.96 (9.61–10.30) | 12.80 (12.40–13.30) | 16.10 (14.90–17.30) | |
| Model 1 | Reference | 1.29 (1.23–1.36) | 1.63 (1.50–1.76) | <0.0001 |
| Model 2 | Reference | 1.00 (0.95–1.05) | 1.18 (1.09–1.28) | 0.0040 |
| Model 3 | Reference | 1.04 (0.98–1.10) | 1.22 (1.12–1.33) | <0.0001 |
| Sensitivity analysisb | Reference | 1.04 (0.99–1.10) | 1.20 (1.10–1.30) | <0.0001 |
| Sensitivity analysisc | Reference | 1.04 (0.98–1.11) | 1.24 (1.12–1.38) | 0.0003 |
| Sensitivity analysisd | Reference | 1.02 (0.94–1.05) | 1.15 (1.06–1.26) | 0.0022 |
| Sensitivity analysisf | Reference | 1.03 (0.97–1.10) | 1.21 (1.10–1.34) | 0.0010 |
Model 1: unadjusted
Model 2: adjusted for age, gender, and baseline SUA
Model 3: further adjusted for education, income, smoking status, alcohol use, physical activity, history of hypertension, diabetes and dyslipidemia, antihypertensive agents, hypoglycemic agents, lipid-lowering agents, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, estimated glomerular filtration rate, and high-sensitivity C-reactive protein
Abbreviations: CI Confidence interval, HR Hazard ratio, SUA Serum uric acid
aIncidence rate per 1000 person-years
bSensitivity analysis was adjusted for average body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, estimated glomerular filtration rate, high-sensitivity C-reactive protein, and SUA during the exposure period and other variables at baseline in model 3
cSensitivity analysis excluded incident myocardial infarction or death within the first 2 years of follow-up and adjusted for variables in model 3
dSensitivity analysis was adjusted for metabolic syndrome instead of its components and other variables in model 3
eSensitivity analysis was conducted using Fine-Gray competing risk model considering non-MI deaths as competing risk events and adjusted for variables in model 3
fSensitivity analysis excluded participants with cardiovascular or cerebrovascular disease and adjusted for variables in model 3
Fig. 3Kaplan–Meier curves of A myocardial infarction and B all-cause mortality incidence rate by serum uric acid trajectories
Fig. 4Subgroup analyses for the association with serum uric acid trajectories with risk of myocardial infarction and all-cause mortality. Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio. Adjusted for age, gender, education, income, smoking status, alcohol use, physical activity, history of hypertension, diabetes and dyslipidemia, antihypertensive agents, hypoglycemic agents, lipid-lowering agents, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, estimated glomerular filtration rate, high-sensitivity C-reactive protein. and baseline serum uric acid other than variables for stratification